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Abstract A formulary decision was made at a large provider
of acute hospital services in Surrey to replace piperacillin/
tazobactam with amoxicillin+temocillin for the empiric treat-
ment of severe hospital-acquired pneumonia. This decision
was made because the use of broad-spectrum-β-lactam anti-
biotics is a known risk factor forClostridium difficile infection
(CDI) and for the selection of resistance. After the antibiotic
formulary was changed, a retrospective audit was conducted
to assess the effect of this change. Data from patients
hospitalised between January 2011 and July 2012 for severe
hospital-acquired pneumonia and treated empirically with
piperacillin/tazobactam or amoxicillin+temocillin were
reviewed retrospectively. Clinical characteristics of patients,
data related to the episode of pneumonia, clinical success
and incidence of significant diarrhoea and CDI were analysed.
One hundred ninety-two episodes of severe hospital-acquired
pneumonia in 188 patients were identified from hospital re-
cords. Ninety-eight patients received piperacillin/tazobactam
and 94 amoxicillin+temocillin. At baseline, the two treatment
groups were comparable, except that more patients with renal
insufficiency were treated with piperacillin/tazobactam. Clin-
ical success was comparable (80 versus 82 %; P=0.86), but
differences were observed between piperacillin/tazobactam
and amoxicillin+temocillin for the rates of significant diar-
rhoea (34 versus 4 %, respectively; P<0.0001) and for CDI
(7 versus 0 %, respectively; P<0.0028). This preliminary
study suggests that the combination amoxicillin+temocillin
is a viable alternative to piperacillin/tazobactam for the treat-
ment of severe hospital-acquired pneumonia. This combina-
tion appears to be associated with fewer gastrointestinal ad-
verse events. Further studies are needed to evaluate the place
of amoxicillin+temocillin as empiric treatment of severe
hospital-acquired pneumonia.
Introduction
The widespread use of broad spectrum antibiotics has led to
the emergence of multidrug-resistant bacteria, especially
multidrug-resistant Gram-negative bacilli [1–3]. Since the fu-
ture of all antibiotics is threatened by the spread of multidrug-
resistant (MDR) bacteria, it is important to decrease their glob-
al consumption and to favour narrow spectrum antibiotics
whenever possible [4, 5].
Piperacillin/tazobactam is often used as first-line treatment
for several types of severe infection including: severe hospital-
acquired pneumonia (HAP), septicaemia/sepsis, urosepsis, se-
vere cholecystitis/cholangitis and neutropenic sepsis. To limit
the use of this broad-spectrum antibiotic, a formulary decision
was made at a large provider of acute hospital services in
Surrey (serving a population of 380,000 people) to replace
piperacillin/tazobactam with an original antibiotic combina-
tion (amoxicillin plus temocillin) for the empiric treatment
of severe hospital-acquired pneumonia. This combination
covers Streptococcus pneumoniae, Enterobacteriaceae (in-
cluding extended-spectrum β-lactamase (ESBL)-producing
organisms) and Haemophilus influenzae, but not Pseudomo-
nas aeruginosa nor Staphylococcus aureus. For this reason,
the hospital formulary was updated to cover the following
situations: (i) teicoplanin instead of amoxicillin if
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methicillin-resistant Staphylococcus aureus was suspected,
(ii) add flucloxacillin to amoxicillin plus temocillin for
methicillin-sensitive S. aureus or (iii) add metronidazole if
aspiration pneumonia was thought likely.
Temocillin is a narrow spectrum antibiotic active against
Gram negative bacteria and more particularly against the En-
terobacteriaceae and Haemophilus influenzae, while non-fer-
menters, Gram-positive aerobes and strict anaerobes are not
included in its spectrum [6]. Temocillin has been marketed
since 1984 in Belgium, Luxembourg and since 1989 in the
United Kingdom. In December 2014, it has been approved in
France in response to the rise in ESBL-producing coliforms.
In vitro and clinical data suggest temocillin is a potential al-
ternative to carbapenems because of its stability against most
β-lactamases including ESBLs, AmpC enzymes and even
some carbapenemases [7–10].
After the antibiotic formulary was changed, a retrospective
audit was conducted to assess the effect of this change.
Materials and methods
This audit was a service evaluation and was conducted for
internal hospital guidance. It was initiated at the request of
the Infection Control Committee and the Antibiotic Group in
Ashford & St. Peter’s Hospitals NHS Foundation Trust. Ac-
cording to the UK national research ethics service, neither
consent, nor ethical approval was needed as the data collection
was retrospective and for local guidance, not a formal research
project.
A sample size calculation was performed based on a non-
inferiority methodology. Aminimum of 92 episodes per group
would be needed to detect a difference of 15 % between
groups based on the following assumptions: alpha of 5%, beta
of 90 % and clinical cure rate set at 86 % in each group.
The formulary decision replacing piperacillin/tazobactam
with amoxicillin plus temocillin took place in November
2011. From our clinical coding department, 247 episodes of
severe HAP were retrieved. Those treated with piperacillin/
tazobactam were collected from January 2011 to November
2011 and those treated with amoxicillin plus temocillin from
November 2011 to July 2012.
Medical notes of patients with HAP were then retrieved
and reviewed. The diagnosis of severe HAP was confirmed
if all of the following factors were present: onset≥48 h after
hospitalisation, new/persistent otherwise unexplained infil-
trates on chest X-ray, increased oxygen requirement, temper-
ature <36 or >38.4 °C, CURB-65 score >2. Although the
CURB-65 score has been validated for community-acquired
pneumonia (CAP) [11] and not HAP, it may help clinicians to
differentiate between severe HAP and mild HAP.
In accordance with local guidelines, daily doses of antibi-
otics were: 4 g/0.5 g piperacillin/tazobactam three times daily;
1 g amoxicillin three times daily and 2 g temocillin twice daily
[or 1 g twice daily if creatinine clearance (CrCl) 30–60 mL/
min or 1 g once daily if CrCl 10–30 mL/min]. Patients treated
empirically with piperacillin/tazobactam or amoxicillin plus
temocillin for at least 3 days were included in the present
analysis. Patients with penicillin allergy or those who received
a concomitant antibiotic not included in local guidelines were
excluded. Patients having ventilated-acquired pneumonia
(VAP) were also excluded as empiric treatment remains piper-
acillin/tazobactam.
Patient demographics, creatinine clearance (CrCl), lung in-
jury prediction score, co-morbidities, microbiological data,
prior and concomitant antibiotics, hospitalisation time, clinical
outcome and in-hospital mortality were collected. Clinical
outcome was assessed on day 3, 5 and 7 and validated by
two blinded reviewers based on the analysis of the medical
notes, clinician documentation of the chest X-ray findings and
its progress, patient’s clinical progress and clinical observa-
tions (e.g., oxygen saturation, respiratory rate, and tempera-
ture) and infection markers from blood pathology results.
Clinical outcomes were recorded as cure (improved clinical
condition on day 5), failure (worsening of the clinical condi-
tion), relapse (recurrence of signs of pneumonia after day 7
among those who were cured) or indeterminate (inability to
decide on the clinical outcome on day 3). Unless the assess-
ment of efficacy was unclear, each reviewer validated differ-
ent cases.
Incidence of significant diarrhoea (at least two episodes of
type 6 or 7 stools on Bristol stool chart in 24 h) and CDI cases
were recorded. For the patients included prior to 2012, the
diagnosis of CDI relied on the detection of toxins A and B
in faeces. As the sensitivity of these tests has been questioned
in the literature [12], a two-step process (glutamate dehydro-
genase and toxin immunoassay) is now in place in the
hospital.
Statistical analyses were performed using JMP 10 (SAS
Institute). Continuous and nominal variables were compared
using Student's t-test and Fisher’s exact test, respectively.
Each variable that was statistically significant on univariate
analysis was entered into a multivariate model. Effect likeli-
hood ratio tests after nominal logistic fit were performed for
multivariate analysis.
Results
Demographic, baseline clinical data
One hundred ninety-two episodes of severe HAP in 188 pa-
tients met the inclusion criteria. Ninety-four episodes of HAP
in 92 patients were treated with piperacillin/tazobactam and
98 episodes in 96 patients with amoxicillin plus temocillin.
Clinical characteristics of patients are shown in Table 1. The
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two treatment groups were comparable in terms of demo-
graphics and severity of disease. However, more patients with
renal insufficiency were treated with piperacillin/tazobactam.
About a fifth of the patients (36/188) were hospitalised
in the intensive care unit (ICU), and 30/36 developed acute
respiratory distress syndrome (ARDS). All patients who
developed ARDS had a lung injury prediction score
(LIPS) score of ≥7 and all patients with a LIPS score of
≥8 developed ARDS.
Characteristics of HAP episodes and antibiotic treatment
Identification of a bacterial pathogen was not reported in 85%
of cases. Two patients in the piperacillin/tazobactam group
had P. aeruginosa in their sputum compared to none in the
amoxicillin plus temocillin group. No patients in either group
had positive blood cultures for P. aeruginosa. One patient in
the piperacillin/tazobactam group had a positive sputum cul-
ture for S. aureus compared to no patients in the amoxicillin
plus temocillin group. No patients in either group had a pos-
itive blood culture for S. aureus.
Patients were treated according to the local guidelines.
Three episodes in the piperacillin/tazobactam group re-
ceived concomitant teicoplanin and one episode also re-
ceived metronidazole. In ten episodes in the amoxicillin
plus temocillin group patients received concomitant met-
ronidazole. Table 1 shows the duration of antibiotic thera-
py and length of hospital stay, which were comparable
between the two groups.
Clinical outcome and in-hospital mortality
Clinical cure rate was 80 % [75/94] for piperacillin/
tazobactam and 82 % [80/98] for amoxicillin plus temocillin,
whilst clinical failure occurred in 15 and 12 episodes, respec-
tively (Fig. 1). Four relapses occurred in both of the study
groups, and two episodes were deemed indeterminate in the
amoxicillin plus temocillin group.
On univariate analysis, treatment duration (P<0.0001), the
presence of renal insufficiency (P=0.04), a Charlson’s comor-
bidity index ≥6 (P=0.0001) and the development of ARDS
(P=0.04) significantly affected clinical outcome. Multivariate
analysis showed that ARDS, Charlson’s comorbidity index ≥6
and treatment durationwere independent predictors for overall
clinical cure (P<0.0001).
Overall, in-hospital patient mortality was 14 % [27/192]
but mortality due to pneumonia was 9 % [17/192].
Where patients developed ARDS, in-hospital mortality
was significantly higher (37 % [11/30] versus 10 % [16/
162], respectively; P=0.0005). Overall relative risk (RR) for
mortality in the presence of ARDS was 3.7 (95 %, confidence
interval (CI) 1.9–7.2). No difference in overall mortality and
in mortality related to the episode of pneumonia was observed
between groups, neither in patients hospitalised in ICU nor in
those developing ARDS (see Table 2). Univariate analysis
found that the development of ARDS, a Charlson’s comorbid-
ity index ≥6 (P=0.02) and treatment duration (P<0.0001)
affected mortality. Multivariate analysis found that these three
variables were all independent predictors for in-hospital mor-
tality (P<0.0001). A sub-analysis of the impact of the length
Table 1 Characteristics of
patients and infections Characteristics Piperacillin/tazobactam Amoxicillin+temocillin P-value
Patients
Number of patients 92 96 NS
Male (%) 36 (39 %) 47 (49 %) NS
Age (year)a 79±13 80±14 NS
Patients with renal insufficiency (%)b 49 31 <0.05
Charlson’s comorbidity index 5.9±2.4 6.0±2.5 NS
Hospitalised in intensive care 18 (20 %) 18 (19 %) NS
Episodes of hospital-acquired pneumonia (HAP)
Number of episodes 94 98 NS
LIPS scorea 5±2.0 5±1.8 NS
ARDS (n) 16 14 NS
Length of hospital stay (days)a 30±21 29±18 NS
Duration of antibiotic treatment (days)a 6.7±1.6 6.8±1.5 NS
Previous antibiotic treatment (%)c 50 47 NS
NS not significant, LIPS lung injury prediction score, ARDS acute respiratory distress syndrome
a Mean±standard deviation
b Creatinine clearance<60 mL/min
c Defined as the administration of any antibiotic prior to the administration of piperacillin/tazobactam or amox-
icillin plus temocillin during the same hospital stay as the episode of HAP
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of treatment on the overall mortality showed that a treatment
of 5 days or less is strongly associated (P<0.0001) with an
increased mortality (38 % [15/39]) when compared to longer
treatment durations (8 % [12/153]). A trend for higher mortal-
ity is still observed when the treatment duration is of 7 days or
less (16 % [25/155]) when compared to longer treatment du-
rations (5 % [2/37]), although this difference does not reach
statistical significance.
Incidence of significant diarrhoea andClostridium difficile
infection
As shown in Fig. 2, in 34 % [32/94] of episodes treated with
piperacillin/tazobactam, patients developed significant diar-
rhoea versus 4 % [4/98] for amoxicillin plus temocillin
(P<0.0001). This corresponded to a RR of developing severe
diarrhoea associated with piperacillin/tazobactam treatment of
8.3 [95 % CI 3.1–22.7] when compared to amoxicillin plus
temocillin.
The difference in the number of CDI cases between the two
treatment groups also achieved statistical significance (7 %
[7/94] of episodes for piperacillin/tazobactam versus 0 %
[0/98] for amoxicillin plus temocillin, P=0.006). No other
factor affecting the incidence of CDI was identified on uni-
variate analysis and, on multivariate analysis, the only inde-
pendent predictor for CDI identified was the treatment group
(P=0.001).
Occurrence of diarrhoea increased hospital length of stay
(LoS) (27±2 days for episodes without diarrhoea versus 38±
3 days for episodes with diarrhoea, P=0.005) and CDI further
increased LoS (29±1 days for episodes without CDI versus
49±7 days for episodes with CDI, P=0.0077).
Discussion
A change in treatment from piperacillin/tazobactam to
temocillin plus amoxicillin for HAP reduced the overall con-
sumption of piperacillin/tazobactam by 30 % in our centre.
The retrospective audit found no difference of clinical out-
come between the two groups, although significant differ-
ences were observed in terms of gastrointestinal events. There
were fewer cases of significant diarrhoea and no cases of CDI
reported in patients managed with amoxicillin plus temocillin.
Fig. 1 Clinical efficacy of treatment groups. Comparison of clinical
outcomes between piperacillin/tazobactam (TZP) [white bar] and
amoxicillin plus temocillin (AMX+TMO) [black bar] groups. No
significant difference was observed






Overall mortality 15 % [14/94] 13 % [13/98] NS
Hospitalised in ICU 44 % [8/18] 28 % [5/18] NS
ARDS 38 % [6/16] 36 % [5/14] NS
Mortality due to pneumonia 11 % [10/94] 7 % [7/98] NS
Hospitalised in ICU 33 % [6/18] 11 % [2/18] NS
ARDS 25 % [4/16] 14 % [2/14] NS
NS not significant, ICU intensive care unit, ARDS acute respiratory dis-
tress syndrome
Fig. 2 Adverse events of treatment groups. Frequency of significant
diarrhoea and hospital-acquired Clostridium difficile infection (CDI)
associated with piperacillin/tazobactam (TZP) [white bar] and
amoxicillin plus temocillin (AMX+TMO) [black bar]. Significant
differences were observed between groups
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Combination therapy may offer an increased likelihood of
adequate coverage for the potential pathogens causing the
infection and a synergistic effect [13]. Those factors may be
beneficial in terms of clinical outcome, for preventing and
delaying the emergence of resistance and for shutting off toxin
production [13]. Synergism with dual beta-lactam therapy
may result from the enhanced inhibition of the penicillin-
binding proteins (PBPs) and could offer better outcomes with
less toxicity than beta-lactam-aminoglycoside combination
regimens. Combination regimens including temocillin have
been reported in in vitro studies where its association with
compounds such as ampicillin, flucloxacillin and ticarcillin
were synergistic or partly synergistic with an enhanced activ-
ity against some strains of Pseudomonas or Staphylococcus
[14].
The rate of diarrhoea associated with piperacillin/
tazobactam reported in the present audit is high but similar
to the percentage of diarrhoea reported by Bow et al. [15].
This may reflect the demographics of the population which
included a high proportion of elderly patients where an
increased rate of adverse events associated with
piperacillin/tazobactam has already been reported by
Karino et al. [16].
There is a lack of consensus in the published literature
relating to the incidence of gastrointestinal complications
and the use of piperacillin/tazobactam. It has been reported
that piperacillin/tazobactam inhibits growth and toxin produc-
tion of C. difficile [17] and that during a shortage of
piperacillin/tazobactam when replacement antibiotics were
initiated, rates of CDI increased by 200 % or more in two
institutions [18, 19]. However, the use of piperacillin/
tazobactam has also been associated with CDI. In one institu-
tion, the incidence of CDI decreased by 47 % during the
period in which there was a shortage of piperacillin/
tazobactam [20]. Other studies have identified piperacillin/
tazobactam as a risk factor for CDI [21–23]. In the present
study, a CDI rate of 7 % was reported, a figure similar to other
reports [24, 25]. Compared to cephalosporins and
clindamycin, piperacillin/tazobactam is not a strong inducer
of CDI; yet, a recent meta-analysis reported a 50 % increased
risk of hospital-acquired CDI to be associated with penicillin
combination antibiotics such as piperacillin/tazobactam [26].
In our centre, the use of piperacillin/tazobactam rose from 92
defined daily dosage (DDD) per month in 2008 to 267 DDD
per month in 2011. This increased usage may account for the
differences in diarrhoea and CDI in this audit. We have also
observed that a change from branded piperacillin/tazobactam
to a generic seems to be associated with an increase in side
effects, although these data were not collected in the current
audit.
The present study supports the use of alternatives to broad-
spectrum antibiotics, not only because broad spectrum agents
are associated with the development of multidrug-resistant
bacteria, but also because of their association with CDI [27].
In this context, temocillin will provide an alternative choice as
animal models have not reported any induction of antibiotic-
associated colitis after temocillin treatment [28]. Human stud-
ies also suggest temocillin is safe for the individual patients
with regards to ecological side effects [7, 29].
In our hospital in 2013 and 2012, two and six cases of
CDI associated with the use of piperacillin/tazobactam
were reported. These cases accounted for 20 and 42 %
of all our hospital-acquired cases in 2013 and 2012, re-
spectively, while in 2011 and 2010, the cases associated
with piperacillin/tazobactam (17 and 23 cases, respec-
tively) accounted for 71 and 62 % of all our hospital-
acquired cases. This is consistent with the findings of a
recent Cochrane review which highlighted that interven-
tions to reduce excessive antibiotic prescribing to hospi-
tal inpatients can reduce antimicrobial resistance or
hospital-acquired infections, and that interventions to in-
crease effective prescribing can improve clinical outcome
[30].
There are limitations to the use of the combination amox-
icillin plus temocillin that need to be highlighted. This com-
bination is only suitable in centres with a low incidence of
P. aeruginosa (< than 5 %) as neither antibiotic is active
against it. Moreover, it is important to include provisions for
other organisms not covered by the combination (such as
S. aureus and anaerobes) which is not appropriate empiric
treatment for VAP.
Data collected in the present audit were recovered retro-
spectively. It is widely acknowledged that retrospective stud-
ies are exposed to bias, and that caution should be exercised in
interpreting these findings. Only a limited number of patients
included in the present audit had a positive bacterial culture.
The diagnostic sensitivity of the sputum culture is known to be
variable, between 29 and 94% [31]. Such variable results may
be related to inadequate sampling of sputum (difficulty of
elderly patients to produce enough sputum), delayed process-
ing of sputum specimens, and prior antimicrobial therapy
(which occurs in 50 % of the patients in the present study)
[31].
In conclusion, our audit suggests that amoxicillin plus
temocillin is a viable therapeutic option in the treatment of
severe HAP, and is associated with a favourable safety profile
when compared to piperacillin/tazobactam. Further non-
inferiority randomised controlled trials are needed to confirm
those preliminary data, and to better define the place of amox-
icillin plus temocillin as potential empirical treatment of se-
vere HAP. Audits are necessary to validate formulary changes
and sharing these data may encourage other centres to conduct
randomised controlled trials using this or another combination
of antibiotics in order to minimize the over-use of broad-
spectrum antibiotics such as piperacillin/tazobactam and
carbapenems.
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